Please login to the form below

Trelegy

This page shows the latest Trelegy news and features for those working in and with pharma, biotech and healthcare.

GSK seeks EU approval for Trelegy in adult asthma patients

The European Medicines Agency has accepted the regulatory submission for expanded use of GlaxoSmithKline’s Trelegy in adult asthma patients. ... Trelegy is a key drug in GSK’s arsenal, especially in its efforts to revive sales of its respiratory

Latest news

Novartis strengthens case for its combination asthma drug

However, it was still able to establish its next-generation of respiratory products – this includes Trelegy (vilanterol/umeclidinium/ fluticasone furoate), which brought in £139 in Q3 and Nucala (mepolizumab), which brought
GSK boosts outlook thanks to strong respiratory and vaccine sales

New launches for respiratory products Nucala (mepolizumab) and Trelegy (vilanterol/umeclidinium/ fluticasone furoate) helped boost revenues in this area, bringing in £203m and £139m respectively. ... This was due to Nucala receiving EU approval for self
AZ builds case for its COPD triple as it chases GSK’s Trelegy

After a slow start, Trelegy (vilanterol/umeclidinium/ fluticasone furoate) is showing signs of gathering momentum, with sales more than doubling to around $250m in the first half of this year. ... First to market in Europe was Chiesi with its Trimbow
Advair generics and acquisitions to hit GSK in 2019

These include three-drug COPD product Trelegy which realised £156m ($202m) for the year and Nucala, rising 64% to £563m ($729m) in the year.
GSK’s Advair Diskus faces first generic in US

It has also given GSK a bit more time to advance its three-drug COPD product Trelegy (fluticasone furoate/umeclidinium/vilanterol) as well as other new respiratory drugs – although some analysts

More from news
Approximately 6 fully matching, plus 15 partially matching documents found.

Latest Intelligence

Mapping at launch: it’s time to update the satnav

Figure 1 shows a point-in- time value of formulary and guideline mapping for Trelegy, taken in September 2020. ... Figure 2 maps Trelegy’s performance during its first two years on the market (in the UK).